4.29 USD
▲+0.11+4.89%
2026-08-03
市值
$404.63M
市盈率
—
EPS
-1.38
股息率
—
52 周区间
1.35 – 4.83
成交量
604.70K
Beta
0.40
目标价
11.60
52W 低 1.3552W 高 4.83
价格走势
公司简介
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Ta...